AGP Executive Report
Last update: 6 hours agoVaccine & Pharma Watch: Valneva (France) reported half-year 2026 results with €64.0M in product sales, €121.5M cash at end June, and reaffirmed full-year guidance of €135–150M, while pointing to a restructuring program and expecting regulatory decisions for its Lyme disease vaccine candidate within the next 12 months. Urban Health & Climate: A new look at urban heat islands warns that hot-humid tropical cities can’t always afford fixes like shade, green roofs, light-colored surfaces, and cooling infrastructure—especially as El Niño strengthens and could push temperatures to dangerous levels for vulnerable residents. Public Health & Governance: An editorial in Mauritius highlights how drug trade concerns resurface after high-profile arrests, urging a careful approach that respects the rule of law while questioning safeguards around public resources and political responsibility.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.